NCT00242268.

Trial name or title	A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
Methods	A Randomized, Double‐Blinded, Placebo Controlled Trial
Participants	30 Patients with Relapsing‐remitting MS using the McDonald criteria Age between 18 and 55 years Written informed consent EDSS between 0‐ 5.0
Interventions	Intervention group: interferon beta‐1a and simvastatin 40 mg Control group: interferon beta‐1a and placebo
Outcomes	Primary outcomes: new or enlarging T2 lesions on MRI (at 14 months). Secondary Outcomes: relapse rates; disease progression as measured with EDSS and MSFC.
Starting date	October 2005
Contact information	William T. White, Pharm.D., Tel: 205‐979‐7555, Email: bwhite@sdr.us
Notes	Sponsored by Alabama Neurology Associates, PC and Biogen Idec http://clinicaltrials.gov/ct2/show/NCT00242268